Compare Kaltura Inc (KLTR) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kaltura Inc vs Sana Biotechnology Inc — how do they compare? Kaltura Inc trades at $1.32 (market cap $199.08M), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Sana Biotechnology Inc is far larger — about 4.2× Kaltura Inc's market cap, and Kaltura Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kaltura Inc for 21 Days and Sana Biotechnology Inc for 23 Days on average.
| KLTR | SANA | |
|---|---|---|
Market Cap | $199.08M | $836.71M |
Volume | 175,927 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $1.89 | $5.92 |
52-Week Low | $1.08 | $2.68 |
Typical Hold Time | 21 Days | 23 Days |
Enterprise Value | $211.29M | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLTR trades at $1.305, down 1.88% for the day, with a bearish technical signal from moving averages. The company reported revenue of $180.85M for 2025 but remains unprofitable with a net loss of $12.07M, though losses have narrowed significantly since 2022. Recent news highlights include winning the 2026 Digiday Technology Award and being named a leader by Gartner in AI for video platform services.
The outlook is mixed: analyst consensus leans buy (44% buy ratings), and the company shows improving financial trends, but high valuation ratios and persistent net losses present risks. Key catalysts include the commercial rollout of AI products, while execution risks and competitive pressures remain concerns for investors.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative earnings, and substantial cash burn. The technical picture remains bearish with moving averages signaling continued downward pressure, though oscillators show neutral conditions. Recent earnings have been mixed with two misses and one beat against expectations, while analyst sentiment remains overwhelmingly positive with 82% buy ratings.
The outlook hinges on SANA's clinical pipeline success and future revenue generation capabilities. Investment opportunity exists in the company's promising biotechnology platform and strong analyst support, but risks include continued cash burn, lack of current revenue, and execution challenges in bringing therapies to market. The stock represents a high-risk, high-reward biotechnology investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
